VERAXA Biotech AG (NASDAQ: VRXA) provided a corporate and pipeline update on Thursday, detailing progress during the first half of 2026, including continued advancement of its proprietary BiTAC platform and growing interest from potential pharmaceutical partners. The company's pipeline now includes four BiTAC-based T-cell engager programs targeting solid tumors, two bispecific antibody-drug conjugate programs and two non-BiTAC assets available for partnering.
VERAXA said it plans to prioritize investment in its BiTAC portfolio while seeking to monetize selected non-BiTAC programs to help finance future development, with the goal of advancing lead BiTAC-TCE candidate VXA-102 to IND/CTA readiness by early 2028. Company executives also cited strong industry interest in T-cell engager and ADC technologies, noting that recent partnering discussions at the BIO International Convention and other scientific meetings reinforced confidence in the company's differentiated BiTAC platform and its potential to secure strategic collaborations.
VERAXA said it continues to refine both its pipeline and partnering strategy as it advances its next generation of cancer therapies. The company's BiTAC platform is designed to generate bispecific T-cell engagers with improved properties compared to conventional formats, potentially offering better tumor targeting and reduced off-target effects.
The update comes as the biotech sector increasingly focuses on T-cell engagers and ADCs as promising modalities for cancer treatment. VERAXA's approach combines its BiTAC technology with quality-by-design principles to rapidly advance its pipeline into clinical development. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research.
VERAXA's pipeline update and partnering strategy were detailed in the full press release available at https://ibn.fm/xTF5q. For more information about VERAXA Biotech, visit http://ibn.fm/VRXA.
